Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2003
06/12/2003WO2003048130A2 Peroxisome proliferator activated receptor agonists
06/12/2003WO2003048129A1 Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition to a medicament containing same
06/12/2003WO2003048125A1 Aminotetralin derivatives as muscarinic receptor antagonists
06/12/2003WO2003048124A1 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists
06/12/2003WO2003048123A1 Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
06/12/2003WO2003048122A2 Inhibitors of cytosolic phospholipase a2
06/12/2003WO2003048120A2 2-aryl pyrrologpyrimidines for a1 and a3 receptors
06/12/2003WO2003048117A2 Propanolaminomethyltetralines, their preparation and pharmaceutical composition comprising same
06/12/2003WO2003048116A2 Esters and amides as ppar-alpha agonists ____________
06/12/2003WO2003048113A1 Tramadol analogs and uses thereof
06/12/2003WO2003048112A1 Aminoacetonitrile derivatives and their use for controlling parasites
06/12/2003WO2003048109A1 Novel glucagon antagonists
06/12/2003WO2003048106A2 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof
06/12/2003WO2003048101A1 Induction of apoptosis in cancer cells
06/12/2003WO2003048096A1 Substituted aryl-cycloalkanes, and use thereof as anticancer agents
06/12/2003WO2003048081A2 Glycinamides as factor xa inhibitors
06/12/2003WO2003047697A2 Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
06/12/2003WO2003047646A1 Resorbable polymer composition, implant and method of making implant
06/12/2003WO2003047643A1 Controlled release therapeutic wound dressings
06/12/2003WO2003047637A1 Sterilizing tunnel for pharmaceutical containers
06/12/2003WO2003047628A1 Combination of an adenosine a2a receptor agonist and an adrenergic beta-2 receptor agonist
06/12/2003WO2003047627A1 Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a thiazolidinedione derivative, and a use thereof for treating diabetes
06/12/2003WO2003047626A1 Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
06/12/2003WO2003047625A1 Neural transmission promoters
06/12/2003WO2003047624A1 Cell migration inhibitor
06/12/2003WO2003047611A2 Ptp10d, tec and edtp involved in triglycerid-metabolism
06/12/2003WO2003047610A1 Composition and method to increase female sexual desire and sexual satisfaction
06/12/2003WO2003047608A1 A novel herbal chemical composition for the treatment of cancer
06/12/2003WO2003047599A1 An antiinflammatory composition containing catalposide isolated from stem bark of catalpa ovata
06/12/2003WO2003047598A1 Pharmaceutical combinations of adenosine a-2a and beta-2-adrenergic receptor agonists
06/12/2003WO2003047597A1 Combination of crystalline form of a ribofuranosyluronamide derivative and tiotropium salt
06/12/2003WO2003047595A1 Pharmaceutical compositions comprising active vitamin d compounds
06/12/2003WO2003047594A1 Disease treatment using two related compounds wherein at least one of the compound induces a tachyphylactic response which not affect the other compound
06/12/2003WO2003047593A1 Melanogenesis inhibitors and whitening agents comprising ergosterol derivatives and compositions containing ergosterol derivatives
06/12/2003WO2003047591A1 Remedies for primary pulmonary hypertension
06/12/2003WO2003047590A1 Antibiotic formulation and a method of making this formulation
06/12/2003WO2003047589A1 Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
06/12/2003WO2003047588A1 Kit for reducing aching caused by pde-v inhibitors
06/12/2003WO2003047587A1 Platinum derivative pharmaceutical formulations
06/12/2003WO2003047586A1 Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
06/12/2003WO2003047585A1 Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours
06/12/2003WO2003047583A1 Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours
06/12/2003WO2003047582A1 Quinoline derivatives as antitumour agents
06/12/2003WO2003047581A1 Acetylene derivatives having mglur 5 antagonistic activity
06/12/2003WO2003047580A1 Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess therewith
06/12/2003WO2003047579A1 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
06/12/2003WO2003047578A1 Combination of a selective pde4 inhibitor and an adrenergic beta-2 receptor agonist
06/12/2003WO2003047577A2 Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses
06/12/2003WO2003047576A1 Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease
06/12/2003WO2003047574A1 Pharmaceutical composition comprising a derivative of 5-phenoxyalkyl-2,4-thiazolidinedione type and a 4-oxobutanoic acid
06/12/2003WO2003047573A1 Insulin resistance improving agents
06/12/2003WO2003047571A2 Use of a kmo inhibitor for producing a pharmaceutical composition
06/12/2003WO2003047570A1 Benzazole derivatives for the treatment of scleroderma
06/12/2003WO2003047568A1 N-aryl-n'-arylcycloalkyl-urea derivatives as mch antagonists for the treatment of obesity
06/12/2003WO2003047567A1 STABLE, ACID, AQUEOUS SOLUTION CONTAINING α-LIPONIC ACID (DERIVATIVES), METHOD FOR THE PRODUCTION THEREOF AND USE OF THE SAME
06/12/2003WO2003047566A1 Use of coumarin or its hydroxy derivative for the treatment of medium or severe vascular and/or lymphatic edema
06/12/2003WO2003047565A1 Melanogenesis inhibitors and whitening agents comprising egonol derivatives and compositions containing egonol derivatives
06/12/2003WO2003047564A1 Derivative having hiv integrase inhibitory activity
06/12/2003WO2003047563A1 Use of alkanoyl l-carnitine for the treatment of erectile dysfunction
06/12/2003WO2003047562A1 Use of 2-hydroxy or 2-acetyloxy-4-trifluoromethylbenzoic acid derivatives as an agent for the treatment and prevention of mild cognitive impairment
06/12/2003WO2003047561A1 Use of 4-oxobutanoic acid derivatives in the treatment of inflammation
06/12/2003WO2003047560A1 Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
06/12/2003WO2003047559A1 Use of polycyclic phenolic compounds for the treatment of opthalmic diseases
06/12/2003WO2003047558A2 Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
06/12/2003WO2003047557A2 Device and patch for controlling the release of vanillin
06/12/2003WO2003047556A1 Transdermal therapeutic system provided with improved long-term carrying comfort
06/12/2003WO2003047555A1 Transdermal therapeutic systems containing steroid hormones and propylene glycol monocaprylate
06/12/2003WO2003047554A1 Transdermal drug delivery system of strychnine, brucine, securinine and their salts
06/12/2003WO2003047552A2 Pharmaceutical composition comprising a 5ht1 receptor agonist
06/12/2003WO2003047550A1 Aqueous base liquid pharmaceutical compositions in suspension form for the oral administration of ibuprofen
06/12/2003WO2003047543A1 Methods for the treatment of hyperpigmentation of skin
06/12/2003WO2003047537A1 Antimicrobial composition comprising soy oil, rice bran oil and jojoba oil
06/12/2003WO2003047533A2 Composition for treating the surface of the skin
06/12/2003WO2003047529A2 Extended release pharmaceutical tablet of metformin
06/12/2003WO2003047528A2 Supplements containing annatto extracts and carotenoids and methods for using the same
06/12/2003WO2003047524A2 Methods and compositions for modulating the immune system and uses thereof
06/12/2003WO2003047523A2 Raf-mek-erk pathway inhibitors to treat cancer
06/12/2003WO2003047521A2 Composition and method for treatment of otitis media
06/12/2003WO2003047518A2 Cyclodextrin grafted biocompatible amphiphilic polymer and methods of preparation and use thereof
06/12/2003WO2003047517A2 Novel-n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-(trifluoromethyl)-1-h-pyrazole-5-carboxamides as factor xa
06/12/2003WO2003047516A2 Pyrimidine compounds
06/12/2003WO2003047513A2 Method for treating ocular hypertension
06/12/2003WO2003047508A2 Paclitaxel solvates
06/12/2003WO2003047506A2 Peptide agonists of prostate-specific antigen, and uses therefor
06/12/2003WO2003047505A2 Topoisomerase poison agents
06/12/2003WO2003047504A2 Prevention and treatment of androgen-deprivation induced osteoporosis
06/12/2003WO2003047503A2 Delivery of medicaments to the nail
06/12/2003WO2003047501A2 Novel anti-cancer therapeutic compounds
06/12/2003WO2003047500A2 Vaccine and method for treatment of motor neurone diseases
06/12/2003WO2003047499A2 Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting
06/12/2003WO2003047497A1 Isotretinoin nanoparticulate compositions
06/12/2003WO2003047493A2 Stabilized reverse micelle compositions and uses thereof
06/12/2003WO2003047462A1 Polysaccharide-based polmerizable hydrogels
06/12/2003WO2003047417A2 Ep4 receptor agonist, compositions and methods thereof
06/12/2003WO2003047367A1 Solid and stable creatine/citric acid composition(s) and compositions containing carbohydrate(s) or hydrates thereof, method for the production and use thereof
06/12/2003WO2003047350A1 Inhibition of vacuolar proton atpase and/or modulation of acidic organelle function sensitizes
06/12/2003WO2003047341A2 Anti-microbial systems and methods
06/12/2003WO2003032994A3 Novel tri-substituted pyrimidines, method for production and use thereof as medicament
06/12/2003WO2003026641A3 Modulation of stat activity
06/12/2003WO2003024183A3 Wortmannin analogs and methods of using same
1 ... 5437 5438 5439 5440 5441 5442 5443 5444 5445 5446 5447 5448 5449 5450 5451 5452 5453 5454 5455 5456 5457 ... 7860